GlaxoSmithKline has appointed Iain Mackay as its new Chief Financial Officer (CFO), marking another high-level appointment under new CEO Emma Walmsley. He joins from HSBC, where he has been Group Finance Director for the last 8 years.
Iain will join the company on 14 Janurary 2019 and will also be appointed as an Executive Director to the GSK Board. GSK announced in May that its current CFO, Simon Dingemans, is to retire in May 2019.
A chartered accountant, Iain has worked in Asia, the US and Europe and before HSBC was at General Electric, Schlumberger Dowell and Price Waterhouse. He is a trustee of the British Heart Foundation and a member of the Court of the University of Aberdeen.
GSK’s CEO Emma Walmsley said: “I’m delighted to welcome Iain to GSK. As a proven CFO of a complex, regulated global organisation, he brings tremendous finance experience and will be a great addition to the team. He is a strong leader with a track record of driving cost, cash and capital allocation discipline to deliver strategy. These capabilities will be vital as we continue to implement our Innovation, Performance and Trust priorities for the benefit of patients and shareholders.”
Since taking over as CEO in April last year, Walmsley has appointed Luke Miels as head of pharmaceuticals and Hal Barron as head of drug research, as well as finding a new head of digital operations in Karenann Terrell.
Philip Hampton, Chairman, GSK said: “On behalf of the Board I welcome Iain to GSK. His experience in different sectors and in complex, regulated environments will be valuable to the Board and I look forward to his contributions.”
Simon Dingemans will continue to be accountable as CFO for GSK’s financial governance through March 2019. There will be a transition period from 14 January when Iain is CFO Designate, with him taking formal accountability as CFO from 1 April.
By: George Underwood
Source: Pharmatimes
Novartis will acquire Mariana’s lead candidate MC-339, a radioligand therapy (RLT) designed to target small-cell lung cancer. Last year, Mariana had raised $175m in a Series B round from several funds and pharma giant Eli Lilly.
The company’s aspiration to expand the use of its obesity products to cardiovascular indications has been successful. In March, its blockbuster drug Wegovy was approved by the US Food and Drug Administration (FDA) for reducing the risk of cardiovascular diseases in obese or overweight adults.
Massachusetts-based Deciphera brings to the table an extensive kinase inhibitor pipeline, kinase drug discovery expertise, and a strong commercial and sales platform in the US and European markets that is meant to advance Ono’s capabilities and presence in the oncology space.
